Epigallocatechin-3-gallate attenuates oxidative stress and apoptosis in podocytes of focal segmental glomerulosclerosis.

Authors

Xiao Wang, Xiaoyun Shen, Jianbo Qing, Dezhao Lu

Published in

Renal failure. Volume 48. Issue 1. Pages 2711462. Epub Aug 24, 2026.

Abstract

Focal segmental glomerulosclerosis (FSGS) is a major pathological feature of kidney injury, with limited therapeutic options currently available. This study aims to investigate the core mechanisms of podocyte injury in FSGS and the therapeutic potential of the natural extract epigallocatechin-3-gallate (EGCG). Through single-nucleus RNA sequencing of kidney tissues from patients with primary FSGS and an adriamycin (ADR)-induced nephropathy mouse model, we identified a subpopulation of injured podocytes. We found that damaged podocytes exhibited significantly elevated reactive oxygen species (ROS) levels and increased apoptotic activity compared to healthy podocytes. In animal experiments, EGCG treatment effectively reduced the elevation of the urine albumin-to-creatinine ratio, significantly alleviated glomerulosclerosis, and attenuated the ADR-induced decrease in the reduced glutathione/oxidized glutathione ratio in both serum and renal tissues of ADR-treated mice. Furthermore, in vitro treatment of conditionally immortalized mouse podocyte clone 5 confirmed that EGCG significantly reduced ADR-induced ROS production and apoptosis. These findings suggest that EGCG may provide a promising therapeutic approach for alleviating podocyte injury and mitigating FSGS progression.

PMID:
42637672
Bibliographic data and abstract were imported from PubMed on 25 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.